Pulse Bundle

Three vials from growth-hormone-axis research: a CJC-1295 No DAC/ipamorelin blend, a separate sermorelin vial and a separate ipamorelin vial, so ipamorelin appears twice. CJC-1295 No DAC is sermorelin with four amino-acid swaps, so the kit holds two GHRH analogs acting on the same receptor, alongside a ghrelin-receptor agonist. The catalog states no rationale for including both GHRH analogs.

GHRH analogs act on the pituitary's GHRH receptor and ipamorelin on the ghrelin receptor; the synergy idea comes from 1990s IV studies of GHRH plus a different ghrelin mimic (GHRP-6), not these molecules. Sermorelin was FDA-approved (Geref) for children with growth hormone deficiency; small adult studies found raised GH and IGF-1 and modest fat reduction, but researchers concluded the data do not support routine use in normal aging. CJC-1295 No DAC has no human data, and no study has tested this kit or any pair within it.

Three secretagogues on one axis stack growth hormone and IGF-1 stimulation, with possible added fluid retention, joint aches and raised glucose, plus a theoretical cancer concern. Ipamorelin's surgical trial showed more high blood sugar (14.3% vs 8.6%) and low potassium (12.5% vs 3.4%) than placebo. FDA lists fast heart rate and flushing for CJC-1295, flushing is listed for sermorelin, and hypothyroidism appeared in 6.5% of children in sermorelin trials.

CJC-1295 No DAC and ipamorelin are not approved anywhere; FDA advisers voted against compounding both in 2024, and ipamorelin is on the 503B Category 2 safety list. Sermorelin was approved only as Geref (discontinued in 2008 and approval withdrawn in 2009, not for safety or effectiveness reasons) and is compounded only on prescription by pharmacies; a research vial is neither approved nor compounded. All three are prohibited at all times by WADA.